Drug intelligence / Profile preview

MMSN

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems

Overview

Manganese-doped mesoporous silica nanoparticles (MMSN) are engineered nanoparticles designed to serve as a drug delivery system. They are characterized by a high loading capacity, superior biocompatibility, and pH-dependent release behavior. In the context of atherosclerosis treatment, MMSN are utilized as a nanoplatform to deliver therapeutic agents, such as naringenin, to target cells like M1 macrophages, thereby contributing to the reprogramming of macrophage phenotypes.

Other names: manganese-doped mesoporous silica nanoparticles

Beyond the preview

Go deeper on MMSN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMSN.

Explore the full profile